UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):January 20, 2004
Lifecore Biomedical, Inc.
(Exact name of Registrant as specified in its charter)
| | | | | |
| Minnesota | | O-4136 | | 41-0948334 |
| |
| |
|
(State or other jurisdiction of
incorporation or organization) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
3515 Lyman Boulevard
Chaska, Minnesota | |
|
55318 |
| |
|
|
| (Address of principal executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code: 952-368-4300
TABLE OF CONTENTS
Item 7. Financial Statements and Exhibits
(c) The following exhibit is being furnished herewith:
99.1 Press release dated January 20, 2004
Item 9. Regulation FD Disclosure
On January 20, 2004 Lifecore Biomedical, Inc. (“Lifecore”) issued a press release which announced today that it has signed an exclusive agreement with HEXAL AG, a pharmaceutical company based in Holzkirchen, Germany, to supply Lifecore’s generic Hyaluronan knee-injection therapeutic product in Europe.
A copy of Lifecore’s press release is attached hereto as Exhibit (99.1) and hereby incorporated by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | LIFECORE BIOMEDICAL, INC. |
| | | |
| Dated: January 20, 2004 | | /w/ James W. Bracke |
| | |
|
| | | James W. Bracke
President & Chief Executive Officer |
Exhibit Index
| | | |
| 99.1 | | Press release dated January 20, 2004 |
